← Home / Monte Rosa Therapeutics, Inc. (GLUE)
Stock Analysis
Monte Rosa Therapeutics, Inc. (GLUE)
GLUE
GLUE · Market data
16.52 -27.16%
Track GLUE in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when GLUE price is:
52W Range Position
58%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:44 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
17.47
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
7
●
Financial Results
HIGH
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
(Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2026.
8-K Filing • SEC EDGAR
What's Driving GLUE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 17.47 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
25.15
RSI(14)
29.6
Price Chart
GLUE — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$1.4B
Company size
EV
$1.2B
Debt-adjusted value
P/E
-36.1
Not meaningful
P/S
11.3
Premium
P/B
2.7
Balanced
EV/Sales
10.0
Balanced
EV/EBIT
-22.7
Not meaningful
FCF Yield
-1.41%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
4.21M
↘ Weak
📈 Net Income
-44.50M
↘ Negative
Monte Rosa Therapeutics, Inc.
Related Opportunities